Anavex life sciences reports new publication in scientific journal demonstrating the potential of anavex®3-71 to prevent cognitive decline in alzheimer's disease

Anavex®3-71 treatment prevents cognitive impairment, reduces amyloid, and neuroinflammation even after a long drug washout anavex®3-71 halts neurodegeneration and prevents cognitive decline in a transgenic alzheimer's disease model confirmation of anavex's upstream sigmar1 oral small molecule drug platform in alzheimer's disease new york, oct. 25, 2023 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including alzheimer's disease, parkinson's disease, rett syndrome, and other central nervous system (cns) diseases, today reported a new peer-reviewed publication in the journal neurobiology of aging, titled “early treatment with an m1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying alzheimer-like amyloid pathology”, featuring the orally available small molecule anavex®3-71 (af710b).1 this study ascertains potential disease-modifying properties of anavex®3-71 (af710b) on alzheimer's disease (ad) pathology and could be a drug candidate for a once daily oral preventive strategy. anavex®3-71 activates the sigma-1 receptor (sigmar1) and the m1 muscarinic receptor (m1r).
AVXL Ratings Summary
AVXL Quant Ranking